Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Kratom works primarily through its active alkaloids, mitragynine and 7-hydroxymitragynine, which bind to mu-opioid receptors in the brain. This mechanism produces analgesic and sedative effects similar to opioids. At lower doses, the plant also interacts with adrenergic and serotonergic receptors, resulting in stimulant properties. While these pathways are identified in preclinical research, human clinical data remains limited (Evidence Level C).
Can you take kratom with prescription medications?
Kratom poses significant drug interaction risks. It should not be combined with CNS depressants like benzodiazepines, alcohol, or prescription opioids, as this combination can lead to dangerous respiratory depression. Additionally, kratom affects liver enzymes responsible for metabolizing many drugs. Due to limited safety data (Evidence Level C), individuals taking prescription medications should consult a healthcare provider before use.
What is a safe starting dosage for kratom?
Dosage is highly variable and depends on individual tolerance and desired effects. Generally, 1 to 5 grams of raw powder produces stimulant effects, while 5 to 15 grams induces sedation and pain relief. Because potency varies by strain and batch, and clinical guidelines are lacking (Evidence Level C), users should exercise extreme caution. High doses significantly increase the risk of adverse effects like seizures and dependence.
Is kratom safe to use during pregnancy?
No, kratom is considered unsafe during pregnancy and breastfeeding. The active compounds cross the placenta and can lead to neonatal abstinence syndrome, causing withdrawal symptoms in the newborn. Use during pregnancy is also associated with risks of fetal growth restriction. Due to the potential for serious harm, pregnant individuals should strictly avoid this herb.
Can kratom help with opioid withdrawal symptoms?
While anecdotal reports suggest kratom may alleviate opioid withdrawal symptoms, clinical evidence remains insufficient (Evidence Level C). Although mitragynine acts on opioid receptors, substituting one substance for another carries a risk of developing new dependence. Furthermore, the FDA has not approved kratom for treating opioid use disorder, and safety concerns regarding liver toxicity and seizures persist.
Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 27 articles PubMed · modèle : gemma4:31b
Résumé
Kratom (Mitragyna speciosa) is a tropical plant from Southeast Asia with psychoactive properties that produce analgesic, stimulant, and opioid-like effects [PMID:31643556, PMID:36256767].
Contexte
Kratom is an herbal product derived from the leaves of Mitragyna speciosa, a tropical evergreen tree native to Southeast Asia [PMID:31643556, PMID:36256767]. It is consumed globally as a tea, powder, or in capsules [PMID:36256767, PMID:28484399].
Usages traditionnels
Traditionally used in Southeast Asia and parts of Africa to increase the stamina of outdoor laborers, manage pain, treat diarrhea, and stave off fatigue [PMID:36256767, PMID:28484399, PMID:37364801].
Composés actifs
Kratom contains over 40 alkaloids [PMID:34775626, PMID:39640144]. The primary psychoactive compounds are mitragynine and 7-hydroxymitragynine [PMID:31643556, PMID:34775626]. Other identified compounds include corynantheidine and speciogynine [PMID:31643556, PMID:37518950].
Mécanisme d'action
Alkaloids in kratom interact with opioid (mu, delta, and kappa), adrenergic, serotonergic, and dopaminergic receptors [PMID:38217374, PMID:34775626, PMID:36594896]. Mitragynine and 7-hydroxymitragynine act as partial mu- and kappa-opioid agonists [PMID:31643556].
Preuves cliniques
Preuve BPain Management
Preclinical evidence and one randomized controlled trial support its therapeutic value as an analgesic [PMID:37266188].
Preuve COpioid Use Disorder/Withdrawal
Used as an alternative for treating opioid withdrawal symptoms and managing cravings [PMID:31999896, PMID:37266188].
Preuve DSleep
Bedtime use was associated with modest increases in self-reported sleep duration and quality in a 15-day study of adults [PMID:40839514].
Preuve CCognition
Mitragynine may adversely affect cognitive performances by disrupting synaptic plasticity and brain activity [PMID:39643045].
Sécurité et effets indésirables
Adverse effects include potential for dependence, withdrawal, and life-threatening toxicity [PMID:31999896]. Specific risks include acute liver injury and hepatotoxicity characterized by cholestatic patterns and perivenular necrosis [PMID:31643556, PMID:35399621, PMID:31919755]. Other reported effects include cardiotoxicity, seizures, psychosis, and cardiovascular, gastrointestinal, and psychiatric issues [PMID:34646135, PMID:28484399, PMID:35645563].
Grossesse et allaitement
In-utero exposure has raised concerns regarding the risk of neonatal abstinence syndrome [PMID:35645563]. Scientific evidence specific to therapeutic and adverse effects in pregnancy is limited to a few case reports [PMID:37679866].
Interactions médicamenteuses
Kratom's bioactive alkaloids can significantly impact the pharmacokinetics and pharmacodynamics of concomitant medications, though specific human drug interaction studies are limited [PMID:40522665, PMID:29255059].
Posologie et administration
Some individuals using kratom for chronic pain, depression, and anxiety typically consume 1-3 grams daily in powder form [PMID:39640144]. No PubMed data available. Consult a healthcare provider.
Synthèse des preuves
The evidence is primarily based on reviews, case reports, and preclinical data (Levels C and D), with very limited high-level clinical trial data (Level B).
Sources PubMed
1.PMID: 31999896 (2020) — Kratom (Mitragyna speciosa): Friend or Foe? · The primary care companion for CNS disorders
2.PMID: 38217374 (2024) — An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. · Expert review of clinical pharmacology
3.PMID: 31643556 (2012) — The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. · International journal of legal medicine
4.PMID: 36256767 (2026) — Kratom (Mitragyna speciosa): worldwide issues. · Current opinion in psychiatry
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
PMID: 37983284 (2023) — Pharmacology and toxicology of kratom. · Bratislavske lekarske listy
7.PMID: 36594896 (2023) — Kratom Alkaloids: A Blueprint? · ACS chemical neuroscience
8.PMID: 37518950 (2023) — Biosynthesis of kratom opioids. · The New phytologist
9.PMID: 34775626 (2022) — Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa). · Journal of clinical pharmacology
10.PMID: 35645563 (2022) — Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. · Substance abuse : research and treatment
11.PMID: 36883326 (2023) — Directed Biosynthesis of Mitragynine Stereoisomers. · Journal of the American Chemical Society
12.PMID: 28947930 (2017) — Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse. · ACS medicinal chemistry letters
13.PMID: 28484399 (2017) — Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom. · Frontiers in psychiatry
14.PMID: 37266188 (2023) — Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review. · Current addiction reports
15.PMID: 35767669 (2022) — Kratom use as more than a "self-treatment". · The American journal of drug and alcohol abuse
17.PMID: 29255059 (2018) — Pharmacologic and clinical assessment of kratom. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
18.PMID: 37679866 (2024) — Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy. · Journal of midwifery & women's health
19.PMID: 40839514 (2025) — Is bedtime use of kratom (Mitragyna speciosa) a sleep aid or disruptor? Examining its daily effects and individual differences. · Experimental and clinical psychopharmacology
20.PMID: 39643045 (2025) — Exploring the cognitive effects of kratom: A review. · Behavioural brain research
21.PMID: 34646135 (2021) — The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review. · Frontiers in pharmacology
22.PMID: 40522665 (2025) — Evaluating the drug interactions in kratom usage: clinical application. · Expert opinion on drug metabolism & toxicology
23.PMID: 39640144 (2024) — Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant. · Cureus
24.PMID: 32153252 (2020) — Public Perceptions toward Kratom (Mitragyna Speciosa) Use in Malaysia. · Journal of psychoactive drugs
25.PMID: 37364801 (2023) — Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects. · Journal of ethnopharmacology
26.PMID: 36798621 (2023) — Investigating the Impact of Kratom (Mitragyna speciosa) Use Upon Male Sexual Health. · Research and reports in urology